Ipca Laboratories has entered into an agreement with a leading product development partnership, Medicines for Malaria Venture (MMV), to co-develop a novel antimalarial co-formulation named ‘Atoguanil’.
Atoguanil has the potential to provide a lower cost alternative, making such products more accessible to people living in malaria-endemic countries for prophylaxis.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
